InvestSMART

Dimerix Limited (ASX: DXB) - Announcements

Current share price for DXB : $0.310 0.015 (4.62%)+

ASX company news and announcements for Dimerix Limited (DXB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Dimerix Limited (DXB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Dimerix Limited (DXB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Dimerix Limited (DXB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$186 LR 3.10.5A Disclosure 28 Feb 2018 10:05AM $0.145 $0.310 risen by 113.79%
$186 Appendix 3B and Cleansing Notice 28 Feb 2018 9:54AM $0.145 $0.310 risen by 113.79%
$186 Change in substantial holding 27 Feb 2018 12:35PM $0.150 $0.310 risen by 106.67%
$186 Half Year Report and Financial Statements 26 Feb 2018 7:27PM $0.150 $0.310 risen by 106.67%
$186 Oversubscribed Placement to Raise a Further $4.5m 21 Feb 2018 9:36AM $0.135 $0.310 risen by 129.63%
$186 Trading Halt 19 Feb 2018 9:07AM $0.135 $0.310 risen by 129.63%
$186 Corporate Presentation 5 Feb 2018 8:27AM $0.120 $0.310 risen by 158.33%
$186 Change of Director's Interest Notice x 2 30 Jan 2018 10:23AM $0.125 $0.310 risen by 148%
$186 Quarterly Review and Appendix 4C 29 Jan 2018 11:11AM $0.125 $0.310 risen by 148%
$186 Appendix 3B 25 Jan 2018 8:26AM $0.125 $0.310 risen by 148%
$186 Results of Entitlement Offer 24 Jan 2018 8:33AM $0.125 $0.310 risen by 148%
$186 Recorded interview with CEO and rights issue update 16 Jan 2018 11:30AM $0.130 $0.310 risen by 138.46%
$186 DMX-200 Dosage Optimisation Study Successfully Completed 8 Jan 2018 8:32AM $0.130 $0.310 risen by 138.46%
$186 Appendix 3B 8 Jan 2018 8:31AM $0.130 $0.310 risen by 138.46%
$186 Proteomics partners diagnostic test with Dimerix kidney drug 14 Dec 2017 8:49AM $0.120 $0.310 risen by 158.33%
$186 Proteomics partnership to improve treatment of CKD 14 Dec 2017 8:24AM $0.120 $0.310 risen by 158.33%
$186 Dispatch of Offer Document and Entitlement and Forms 13 Dec 2017 6:07PM $0.120 $0.310 risen by 158.33%
$186 Audio interview with CEO 11 Dec 2017 10:43AM $0.120 $0.310 risen by 158.33%
$186 Reinstatement to Official Quotation 6 Dec 2017 9:56AM $0.155 $0.310 risen by 100%
$186 Letters to Shareholders and Option Holders 6 Dec 2017 9:56AM $0.155 $0.310 risen by 100%
$186 Appendix 3B 6 Dec 2017 9:56AM $0.155 $0.310 risen by 100%
$186 Entitlement Offer Booklet 6 Dec 2017 9:56AM $0.155 $0.310 risen by 100%
$186 Cleansing Notice 6 Dec 2017 9:56AM $0.155 $0.310 risen by 100%
$186 Entitlement Offer to raise $5.5 million 6 Dec 2017 9:55AM $0.155 $0.310 risen by 100%
$186 Suspension from Official Quotation 5 Dec 2017 9:49AM $0.155 $0.310 risen by 100%

576 - 600 of 725 results

Page 24 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.